S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
LON:AVCT

Avacta Group (AVCT) Share Forecast, Price & News

GBX 121
-1.50 (-1.22%)
(As of 08:25 AM ET)
Compare
Today's Range
118
▼
122.56
50-Day Range
92
▼
130
52-Week Range
87.99
▼
187.98
Volume
842,713 shs
Average Volume
1.53 million shs
Market Capitalization
£337.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlines

AVCT stock logo

About Avacta Group (LON:AVCT) Stock

Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

AVCT Price History

AVCT Stock News Headlines

September 23, 2023 | americanbankingnews.com
Avacta Group (LON:AVCT) Shares Pass Above 200-Day Moving Average of $112.48
September 11, 2023 | msn.com
If I’d invested £1,000 in Avacta shares 5 years ago, here’s how much I’d have now
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 11, 2023 | lse.co.uk
Avacta Group Share Chat
June 21, 2023 | marketwatch.com
Avacta Completes Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
June 21, 2023 | finanznachrichten.de
Avacta Group plc: Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
June 21, 2023 | finance.yahoo.com
Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
June 19, 2023 | marketwatch.com
Avacta Group Says No Fundraising Imminent; Shares Rise
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
June 6, 2023 | uk.finance.yahoo.com
AVCT.L - Avacta Group Plc
April 27, 2023 | finance.yahoo.com
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study
April 5, 2023 | finanznachrichten.de
Avacta Group plc: Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
March 28, 2023 | finance.yahoo.com
Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division
March 16, 2023 | msn.com
Is the Avacta share price dip a buying opportunity?
January 17, 2023 | lse.co.uk
Block Listing Application to AIM
October 21, 2022 | finance.yahoo.com
Avacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 58% of the company
October 1, 2022 | uk.finance.yahoo.com
Avacta Group Plc (AVCT.L)
September 5, 2022 | nasdaq.com
Avacta's AVA6000 Gets FDA Orphan Drug Designation To Treat Soft Tissue Sarcoma; Stock Up
June 30, 2022 | finance.yahoo.com
LG Chem Renews License Triggering Payment to Avacta
May 16, 2022 | benzinga.com
AffyXell Expands its Strategic Partnership With...
April 6, 2022 | proactiveinvestors.com
Avacta full-year results push shares higher
March 19, 2022 | finance.yahoo.com
Is Avacta Group (LON:AVCT) In A Good Position To Invest In Growth?
March 17, 2022 | uk.finance.yahoo.com
What’s next for the Avacta share price?
March 1, 2022 | uk.news.yahoo.com
The Avacta share price: buy or avoid like the plague?
January 18, 2022 | msn.com
Avacta Group selects second pre|CISION drug candidate for development
January 18, 2022 | finance.yahoo.com
Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development
January 10, 2022 | reuters.com
Avacta pauses sales of COVID-19 antigen test to improve Omicron sensitivity
See More Headlines
Receive AVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter.

AVCT Company Calendar

Last Earnings
9/28/2020
Today
9/27/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:AVCT
CUSIP
N/A
CIK
N/A
Web
www.avacta.com
Phone
+44-1904-217070
Fax
N/A
Employees
120
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-39,540,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-132.55%
Return on Assets
-22.85%

Debt

Debt-to-Equity Ratio
341.38
Current Ratio
0.82
Quick Ratio
4.96

Sales & Book Value

Annual Sales
£9.65 million
Price / Sales
34.79
Cash Flow
GBX 8.01 per share
Price / Cash Flow
15.00
Book Value
GBX 7 per share
Price / Book
17.17

Miscellaneous

Outstanding Shares
279,320,000
Free Float
N/A
Market Cap
£335.73 million
Optionable
Not Optionable
Beta
1.46
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. David Alastair Maclaughlin Smith (Age 57)
    CEO & Exec. Director
    Comp: $444k
  • Mr. Tony Gardiner (Age 52)
    CFO, Company Sec. & Exec. Director
    Comp: $273k
  • Ms. Emma Wright
    Group In-House Counsel
  • Mr. Michael Vinegrad
    Group Communications Director
  • Mr. Craig Slater (Age 60)
    Chief Operating Officer of Diagnostics
  • Dr. Matt Johnson
    Chief Scientific Officer of Diagnostics
  • Dr. Neil Bell (Age 65)
    Chief Devel. Officer of Therapeutics
  • Dr. Fiona McLaughlin FSB (Age 53)
    Ph.D., Chief Scientific Officer of Therapeutics Division
  • Mr. David Wilson
    Chief Commercial Officer of Diagnostics
  • Ms. Karen Harrison
    Chief Operating Officer of Therapeutics Division

Key Competitors

View All Competitors













AVCT Stock - Frequently Asked Questions

How have AVCT shares performed in 2023?

Avacta Group's stock was trading at GBX 115 at the beginning of 2023. Since then, AVCT stock has increased by 4.5% and is now trading at GBX 120.19.
View the best growth stocks for 2023 here.

How were Avacta Group's earnings last quarter?

Avacta Group Plc (LON:AVCT) issued its earnings results on Monday, September, 28th. The biotechnology company reported ($3.74) earnings per share for the quarter.

What other stocks do shareholders of Avacta Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avacta Group investors own include Legal & General Group (LGEN), SkinBioTherapeutics (SBTX), Augean (AUG), 7digital Group (7DIG), American Airlines Group (AAL), ACI Worldwide (ACIW), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Amyris (AMRS).

What is Avacta Group's stock symbol?

Avacta Group trades on the London Stock Exchange (LON) under the ticker symbol "AVCT."

How do I buy shares of Avacta Group?

Shares of AVCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Avacta Group's stock price today?

One share of AVCT stock can currently be purchased for approximately GBX 120.19.

How much money does Avacta Group make?

Avacta Group (LON:AVCT) has a market capitalization of £335.73 million and generates £9.65 million in revenue each year. The biotechnology company earns £-39,540,000.00 in net income (profit) each year or GBX (0.14) on an earnings per share basis.

How many employees does Avacta Group have?

The company employs 120 workers across the globe.

How can I contact Avacta Group?

Avacta Group's mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The official website for the company is www.avacta.com. The biotechnology company can be reached via phone at +44-1904-217070.

This page (LON:AVCT) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -